Dexmedetomidine for LISA Procedure in Preterm Infants

• Status: Not yet recruiting
• Trial end date: 2023-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators aim to evaluate: the effectiveness of dexmedetomidine for analgesia and sedation during LISA procedure, without compromising the respiratory drive; the safety of this drug on the preterm infant in a pilot study.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Padova
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

1. Preterm newborns between 26+0 and 36+6 weeks of gestation stratified in two groups:

VLBWI 26-31+6and LBWI 32-36+6.

2. Respiratory distress syndrome requiring surfactant therapy

Exclusion Criteria:

1. Need for emergency intubation in the delivery room

2. Major congenital malformations (such as cardiopathies)

3. Chromosomic abnormalities

4. Fetal Hydrops

5. Hypercapnia: CO2 > 65 mmHg

6. Pneumothorax

7. Hemodynamic compromise